Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Hematol Oncol. 2021 Jun;39(Suppl 1):15–23. doi: 10.1002/hon.2857

Figure 2. MAPK Pathway Mutations in Histiocytic Disorders.

Figure 2.

A. (left) Schematic of MAPK pathway. Under physiologic conditions, the growth factor (gray box) engages the tyrosine kinase receptor that transduces the signal to the nucleus. (right) Activating mutations (such as BRAF-V600E) drive constitutive ERK activation. In the case of LCH, this drives the expression of anti-apoptosis BCL2L1 (BCL-xL) and inhibits CCR7.

B. Stacked bar graphs represent percentages of MAPK pathway mutations in each histiocytic histologic subtype.